Skip to content
Screener

Baxter International BAX Pharmaceuticals — Net Sales

Other segment segments

Medical Products & Therapies
$1.29B+1.8%
Healthcare Systems & Technologies
$705M+0.1%

Similar metrics at other companies

Abbott logo
ABTEstablished Pharmaceuticals — Net Sales
$1.5B+8.4%
NAG
NAGEPharmaceuticals segment — Net Sales
$0—
Central Garden & Pet Company logo
CENTPet — Net Sales
$400.5M-18.7%
CNH Industrial N.V. logo
CNHNet Sales — Net Sales
$2.6B+0.6%
General Mills logo
GISPet — Net Sales
$746.6M+5.8%
Colgate-Palmolive logo
CLPet Nutrition — Net Sales
$1.2B—

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%—
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0×0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / InternationalThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / InternationalThree Months Ended March 31, 2025 / Total
Care & Connectivity Solutions315120435316111427
Front Line Care1987227020275277
Healthcare Systems & Technologies513192705518186704
Injectables & Anesthesia180121301195140335
Drug Compounding—320320—246246
Pharmaceuticals180441621195386581
Other513990483078
Total Baxter$1,435$1,266$2,701$1,490$1,135$2,625

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's pharmaceuticals — net sales?
Baxter International (BAX) reported pharmaceuticals — net sales of $621M in Q1 2026.
How has Baxter International's pharmaceuticals — net sales changed year-over-year?
Baxter International's pharmaceuticals — net sales increased by 6.9% year-over-year, from $581M to $621M.
What is the long-term trend for Baxter International's pharmaceuticals — net sales?
Over 3 years (2021 to 2025), Baxter International's pharmaceuticals — net sales has grown at a 2.9% compound annual growth rate (CAGR), from $2.29B to $2.49B.
What does pharmaceuticals — net sales mean?
Represents the total revenue generated by the Pharmaceuticals segment after deducting returns, allowances, and discounts. It is the primary indicator of the segment's market demand and top-line growth performance.

Ask your AI about Baxter International's pharmaceuticals — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude